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reﬂex testing is based on the use of awell known but outdated biomark-
er which lacks sensitivity and speciﬁcity for the detection of myocardial
injury when compared with cardiac troponin. In addition the Authors
seem to ignore current international guidelines [5], which base the diag-
nosis of myocardial infarction, along with the documentation of objec-
tive evidence of myocardial ischemia, on the correct interpretation of
serial cardiac troponin testing. In fact the analysis of the release kinetics
of troponin may permit the distinction between myocardial damage
caused by myocardial ischemia from myocardial injury caused by
other factors and, possibly, from “false positive” troponin elevations
[5,6]. According to these criteria, the detection of a rise and/or fall pat-The ﬁnding of elevated cardiac troponin levels (i.e. values above the
99th percentile value of the reference population) not related to ischemic
myocardial injury in patients admitted to the emergency department
(ED) with suspected acute myocardial infarction (AMI), represents a
relevant clinical problem, increasingly observed in the last few years,
following the implementation of cardiac troponin (cTnI, cTnT) measure-
ment with high-sensitivity immunoassays [1]. Indeed, the majority of
patients (up to 70%) admitted to the ED with more than one elevated
troponin level may actually have myocardial injury unrelated to acute
coronary syndrome (ACS), especially when they have an age of more
than 70 years, heart failure, and/or other comorbidities [2,3]. In such
patients, the incidence of “false positive” cases, i.e. the ﬁnding of troponin
elevations in the absence of clinically documented myocardial injury, is
actually unknown. Clinical observation however suggests that the per-
centage of “false positive” troponin elevations is extremely low.
In a paper recently published in the journal [4], a clinical case of a pa-
tient presenting to the ED with suspicion of AMI and non-diagnostic
ECG that shows a false positive cTnI result due to the presence in the
blood sample of an analytical interference caused by heterophilic anti-
bodies, has beenpublished. The authors suggest the adoption of an algo-
rithm that allows the prompt detection of the supposed false-positive
result. The described protocol considers the systematic measurement
of CK-MB reﬂex testing in all troponin-positive samples as a reliableMedicine, Fondazione Regione
.tool for the identiﬁcation of biological and analytical interference. This
tern of troponin with at least one value above the 99th percentile
upper reference limit, is needed to make the diagnosis. It is well know,
instead, that the interference of a heterophilic antibody typically causes
a constant (chronic) increase in troponin values, which cannot be
confused with the typical kinetic of the biomarker in AMI patients.
Therefore, the interference by heterophilic antibodies should be differ-
entiated from the huge number of clinical conditions which can cause
a chronic increase in troponin levels [5]. Reﬂex testing is usually per-
formed when the result of a ﬁrst screening test is positive, in order to
improve the speciﬁcity, although at the cost of lower sensitivity. This di-
agnostic strategy, therefore, should be adopted in clinical laboratory
practice to improve speciﬁcity employing a second text more speciﬁc
(but more expensive and time consuming) than the screening text. In
the case of the proposed reﬂex testing [4], the cardiac speciﬁcity of the
second test (i.e. CK-MB) is signiﬁcantly lower than the speciﬁcity of
the screening test (i.e. cardiac troponin) and signiﬁcantly less sensitive
for cardiac damage. As a consequence, the potential clinical advantage
of using a very sensitive and cardio-speciﬁc screening test, such as the
cardiac troponins, appears to be, in the proposed “reﬂex testing” strate-
gy, completely lost. A huge number of clinical studies have deﬁnitively
demonstrated that cardiac troponins (particularly when assayed with
high-sensitivity methods) represent a more cardiac-speciﬁc and sensi-
tive biomarker than CK-MB in cardiovascular risk stratiﬁcation, both in
the general population as well as in patients with cardiac disease [1,7]
conﬁrming that themeasurement of CK-MB is now obsolete. Moreover,
considering that the incidence of heterophilic antibodies in the general
population varies greatly in different studies (from0.17 to 40%) [8,9] the
reﬂex testing proposed, if applied systematically in all patients admitted
to the ED with increased troponin values, may allow the detection of
e43M. Zaninotto et al. / International Journal of Cardiology 177 (2014) e42–e43less than 1% of the total number of patients tested with false positive
values due to the interference by heterophilic antibodies. On the con-
trary, this approach can entail a signiﬁcant underestimation of the num-
ber of patients with cardiac damage (both ischemic and not-ischemic),
thereby missing several patients at mild (or even high) cardiovascular
risk of future major events, who need a strict clinical and therapeutic
monitoring. The problem of analytical interference in immunoassays,
well known to the laboratory professionals and widely described for
several tests (TSH, D-Dimer, HCG etc. including CK-MB), is strictly
method-dependent. Indeed, during the last years there has been
increasing attention by manufacturers to reformulate several assays,
not only those for troponin measurement, in order to reduce this type
of interference [10]. Actually, the more diffuse approach deals with
different technical solutions, sometime very simple and not time-
consuming (serial dilution, treatmentwith polyethylene-glycol, speciﬁc
heterophilic blocking tube devices), that allow the rapid and safe
identiﬁcation of the interference, overtaking the need to modify, on
the basis of a sporadic case, the recommended diagnostic biochemical
algorithm that recognizes the fundamental role of troponins and the
obsolescence/redundance of CK-MB assay.
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